The present work aimed at design and development of subcutaneous implantable drug delivery systems containing progesterone for continuous administration of drug to promote estrus synchronization. With the help of Galaxy extruder the implants were fabricated by extrusion method using polymers ethyl cellulose, cellulose acetate and their combination. The prepared implants were characterized for diameter, uniformity of weight, drug content uniformity, sterility testing, short term stability study and in vivo histopathological study. The in vitro release study in phosphate buffer pH 7.4 at 37 0 C was conducted from the implant matrix as function of concentration of the polymers in implants formulations over a period of 14 to 21 days. The progesterone implants having high polymer concentration releasing less amount of the incorporated drug, compared to drug released from implants having low polymer concentration. Thus polymer concentration effectively controls the amount of drug released. Short term stability of progesterone implants revealed that the implants formulations were stable, and there were no significant changes in physical appearance and drug content of the implants formulations. In vivo histopathological study of prepared progesterone implants in rabbits shows that the polymers used in implants are compatible with the tissues. Data suggest that the implants prepared from cellulose acetate and ethyl cellulose would be promising and interesting non-biodegradable systems for sustained delivery of progesterone for livestock.
Introduction
Estrus detection has been recognized as a time consuming task for formers in order to undertake artificial insemination in livestock. Incorrect timing of insemination due to inaccurate detection of estrus by the farmers often leads to reduced rates of conception. The farmer's ability to detect estrus can be improved by the development of an estrus synchronization treatment. Progesterone is the most commonly used steroidal hormone used for improving feed efficiency and synchronization of estrus, however it is inactive orally except in high dose and has a short biological half-life. These properties make progesterone as model drug for the development of implantable control drug delivery system. The veterinary field is a rich area with opportunity for the application of controlled drug release technology. Because of the large number of food producing animals and the unique problems associated with the administration of drugs to these animals, the potential markets are large as are the potential benefits. The range of therapeutic areas with have need for
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controlled release technologies is limited to those diseases which lead to an economic loss to the grower and/or to applications in which cost effective growth of the animal is achieved. Thus, the major areas of application of controlled release technology include the delivery of therapeutic concentrations of antibiotic or anti parasitic agents, the long term administration of anthelmintic and/or antibacterial agents for growth promotion, the delivery of hormones to achieve accelerated growth or estrus synchronization, and the long term administration of trace nutrients [1] .
Historically pellets or implants were sterile. Small, usually cylindrical shaped solid object were implanted subcutaneously for the purpose of providing the continuous release of medicaments over a prolonged period of time. The pellets, implanted under the skin (usually of the thigh or abdomen) with a special injector or by surgical incisions, provide the patients with an economical means of obtaining long lasting effect of drugs (up to many months after a single implantation) and obviates the need for frequent parenteral or oral hormonal therapy. The implanted pellets containing 100 times the amount of drug (e.g deoxycorticosterone, estradiol, testosterone) were given by other routes of administration, to release slowly into the general circulation. Pellets were formulated without any binders, diluents, to permit total dissolution and absorption of the pellet from the site of implantation [2] .
Historically, the subcutaneous implantation of drug pellets is known to be the first medical approach aiming to achieve prolonged and continuous administration of drugs. This first generation of implantable therapeutic systems was produced by compressing drug crystals, without or with only a small fraction of pharmaceutical excipients into tiny, cylinder-shaped solid pellets that can be readily implanted into a subcutaneous tissue by means of a Kearns pellet injector or by making a small skin incision [3] [4] [5] .
There are several advantages of the implantable drug delivery system including improved efficiency, very effective, small dose is sufficient to elicit the action, reduced side effects, on-spot delivery, convenient therapy, provide linear delivery for long periods of time, from a few weeks to many months, plasma drug levels are continuously maintained in a therapeutically desirable range, harmful side effects from systemic administration can be reduced or eliminated by local administration from a controlled release system. As per current veterinary index, there is no Progesterone implants available into the Indian market, only capsule, injection and tablets are available [6] .
Materials and Methods

Materials
Progesterone gifted sample from Ramson Remedies, Amritsar. Ethyl Cellulose, Cellulose Acetate, Polyvinyl Pyrrolidone, Dimethyl Phthalate, Acetone, Toluene and Ethanol was purchased from Signet Chemical Corp., Mumbai. Other Chemicals like Sodium dihydrogen phosphate, Sodium chloride, Glacial Acetic acid purchased from S.D. Fine Chem. Ltd.
Figure 1: Galaxy Extruder
Galaxy extruder
Galaxy extruder is used to prepare implants. It is fabricated with 316 L grade stainless steel, which is non corrosive with most of the materials. The extruder consist of a cylinder which has an inner diameter of 15 mm and outer diameter 17 mm with a nozzle at the bottom having a diameter of 3 mm. The cylinder is supported by two bent roads mounted on a frame. A plunger with screw and a handle to rotate (to provide pressures needed for extrusion) is mounted on the frame which has a hole with inner threads. Plunger has a diameter of 14.8 mm and a handle is rotated which goes into the cylinder and extrudes the material present in the cylinder through nozzle into long threads The Galaxy extruder used was found suitable to produce long rod shaped implants [7] .
Preparation of implants Procedure
As per formula Table No. 1 Polymer, PVP (channeling agent) and progesterone were powdered and were mixed uniformly in a glass mortar. The mixture was transferred to a china dish and dimethyl phalate (plasticizer) was added and mixed uniformly. 4 ml acetone (0.5ml of Toluene: Ethanol (1:1) mixture for Ethyl Cellulose) and (0.5 ml of Toluene: Ethanol (1:1) mixture and 2 ml acetone for combination of both polymers) was added and mixed thoroughly until it becomes sticky dough mass. The dough mass was fed into the cylinder of the extruder and was extruded in the form of long rods through the nozzle. The rods were kept for overnight drying on a glass plate and cut into 27 mm sized implants. The implants were than dried at 40 0 C to constant weight.
Evaluation of Implants
Diameter of implants
The length and diameter of implants from every batch was measured with the help of vernier caliper [8] .
Weight Variation
Weight variation was checked by weighing three implants individually on electronic balance [8] .
Drug Content Uniformity
Drug content of implants from every batch was estimated. From each batch of implants, 3 samples were taken. The implant was cut in to small pieces and were taken into 50 ml volumetric flask and 45 ml of methanol was added and shaken thoroughly to dissolve the drug and the volume was make up to 50 ml with methanol. This solution was suitably diluted with methanol and assayed for progesterone content by measuring the absorbance at 248.8 nm. Progesterone contents were calculated using the standard calibration curve. The mean percent drug content was calculated as an average of three determinations. The results are given in table [8] .
In vitro Drug Release Studies
The in-vitro drug release studies were conducted by immersing one implant in each vial containing 10 ml of phosphate buffer pH 7.4. The vials were sealed with rubber closures and kept in shaker incubator thermostated at 37 0 C. The dissolution fluid was changed for every 24 hrs [7] .
Throughout the experimental period and replaced with fresh 10 ml phosphate buffer pH 7.4.
The drug concentration in every dissolution fluid was analyzed spectrophotometrically at 248.8 nm after suitable dilution with phosphate buffer pH 7.4.
Tests for Sterility
The sterility test was conducted by membrane filtration method on soybean-casein digest medium [9] .
Drug-Polymer Interaction Study
The IR spectra of progesterone and its formulations were obtained by potassium bromide pellet method using Perkin Elmer FTR series model 1615 Spectrometer.
Stability study
As per International Conference on Harmonization (ICH) guidelines, the selected formulations were wrapped in butter paper and were then stored at 40 0 C / 75 % RH for 3 months and evaluated for their physical appearance and drug content at specified intervals of time.
The selected formulations were wrapped in butter paper and were then stored at 40 0 C / 75 % RH for 3 months and evaluated for their physical appearance and drug content at specified intervals of time [10] .
In Vivo Studies (Tissue-Polymer Interaction Studies)
In-Vivo tissue polymer compatibility study of selected formulations was done in rabbits. The rabbits were maintained on a normal feed for one week prior to the test. After removing the hairs, the rabbits were given an injection of local anesthetics (xylocaine) in thigh region. The sterile implants were then kept subcutaneously in the thigh region of rabbits by making a small surgical incision for a period of 21 days. In each rabbit two incisions were made one with implant (test) and another without implant (controlled). The tissues were collected from both the groups two times once before keeping implants and another after removal of implants [11, 12] . F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  Progesterone  150  150  150  150  150  150  150  150  150  150  Polyvinyl Pyrrolidone  100  150  200  250  100  150  200  250  150  200  Dimethyl Phthalate  200  200  200  200  200  200  200  200  200  200  Cellulose Acetate  800  750  700  650  ------------375  300  Ethyl Cellulose  ------------800  750  700  650  375 
Ingredients (mg) Formulation code
Results and Discussion
Diameters of implants
The diameter determined for formulated Implants are tabulated in Table. Implants mean diameters were almost uniform in all the batches of implants formulations and were found to be in the range of 3.09 mm to 3.88 mm.
Uniformity of weight
The weight variations for all formulations are shown in Table. All the implants passed weight variation test as the % weight variation was within the pharmacopoeias limits. The weights of all the implants formulations were found to be in the range of 118.31 ± 2.34 to 148.07 ± 1.45 mg.
Drug Content Uniformity
The drug content of the formulations was determined according to procedure described in methods. The values are shown in table. The percentage of drug content was found to be between 97.48 ± 0.92 and 99.54 ± 0.52 % of progesterone, which was within acceptable limits.
Test for Sterility
At intervals during the incubation period, and at its conclusion, examine the media for macroscopic evidence of microbial growth. There is no evidence of growth is found, the preparation being examined passes the test for sterility. 
Formulations code
In vitro dissolution studies
The in vitro drug release study of drug implants from each batch (F 1 to F 10 ) was carried out in pH 7.4 phosphate buffer solution for 21 days using the procedure as mentioned earlier. The release of progesterone from implants is shown in table. 3 and 4 and in figure 3 and 4.
From the in vitro dissolution data, it was found that 27.26 %, 29.51 %, 32.08 % and 34.14 % drug is released within a day from implants prepared with cellulose acetate (F 1 to F 4 ) respectively, than the release is slowed and sustained up to 21 days. The maximum amount of drug released from these formulations were found to be 87.90 %, 93.98 %, 98.03 % and 97.89 % respectively in 21 days.
Similarly the implant formulations prepared from ethyl cellulose (F 5 to F 8 ) released 29.13 %, 30.09 %, 32.44 % and 38.18 % progesterone within a day and then sustained the release for a period up to 17 days. The complete drug released from formulations F 5 to F 6 were found to be 98.02 % 98.90 % respectively after 17 days, whereas the formulations F 7 and F 8 released only up to15 and 14 days to a maximum of 97.92 % and 98.02 % of drug respectively.
The implant formulations prepared form the combination of ethyl cellulose and cellulose acetate (F 9 to F 10 ) showed 35.60 % and 32.59 % of initial burst released in one day than the released is sustained up to 21 days. The maximum amount of drug released from these formulations was found to be 94.05 % and 96.24 % respectively. In all the implants formulations it was observed that drug release was effectively modified by polymer and plasticizer concentrations. On increasing the plasticizer concentration the amount of drug release was also increased. In all the implant formulations the release of drug was constant and sustained over a period of 21 days except for the implants prepared from ethyl cellulose which showed a constant drug release up to a period of about 14 days.
Compatibility Study
Compatibility studies were performed using FT-IR spectrophotometer. The IR spectrum of pure drug and physical mixture of drug and polymer were studied by making a KBr disc. The characteristic absorption peaks of progesterone were obtained at different wave numbers in different samples.
The I.R. spectrum of progesterone with excipients is similar to that of pure drug (progesterone). All the characteristic bands of drug are retained in the I.R. spectrum of progesterone implant formulations, indicating that the drug is compatible with excipients present in the formulations. The spectra for all formulations are shown below. 
Stability study
The stability studies were carried out on selected formulations stored at 40 0 C, 75% RH for 3 months.
Implants were analyzed for their physical parameters and drug content at 15 days interval. The residual drug contents of formulations were found to be within the permissible limits. The results were shown in the 
In Vivo Studies (Tissue-Polymer Interaction Studies)
The Histopathological study of the selected formulation in rabbits was done using routine paraffin embedding technique. There was no noticeable changes were observed in the surrounding tissues such as hemorrhages, necrosis, granulomatous lesions. There was no fibrosis in the surrounding tissues including muscular tissues in the all groups. From the Histopathological study it was found that the polymers used in the present implantable drug delivery system are compatible with the surrounding tissues.
Controlled Test Before Implantation
A C B D Conclusion
On the basis of in vitro dissolution profile, progesterone release from implants prepared from cellulose acetate sustained over a period of 21 days. The drug release mechanism for all implant formulations was found to be matrix diffusion controlled. Addition of PVP as channeling agent increases the release of progesterone. Although, the present implantable drug delivery system was not completely optimized to deliver of progesterone for livestock. The in vitro and other data obtained in the study points out the possibility of constructing such a system using cellulose acetate and ethyl cellulose polymers.
